Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4461)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Apr 15, 2023 (publication date) through Jun 1, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Cigrovski Berkovic M, Strollo F. Semaglutide-eye-catching results. World J Diabetes 2023; 14(4): 424-434 [PMID: 37122431 DOI: 10.4239/wjd.v14.i4.424] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v14/i4/424.htm |
| Number | Citing Articles |
| 1 |
George Iype Varughese, Sarita Jacob. Existing and emerging GLP-1 receptor agonist therapy: Ramifications for diabetic retinopathy screening. Journal of the Royal College of Physicians of Edinburgh 2024; doi: 10.1177/14782715241244843
|
| 2 |
Sarita Jacob, George I. Varughese. Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice. Annals of Pharmacotherapy 2024; 58(4): 444 doi: 10.1177/10600280231224039
|
| 3 |
Stefania Chiappini, Rachel Vickers-Smith, Daniel Harris, G. Duccio Papanti Pelletier, John Martin Corkery, Amira Guirguis, Giovanni Martinotti, Stefano L. Sensi, Fabrizio Schifano. Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset. Pharmaceuticals 2023; 16(7): 994 doi: 10.3390/ph16070994
|